Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Forsythe

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Orphanet Journal of Rare Diseases|July 6, 2023
Caregiver burden in Bardet-Biedl syndrome: findings from the CARE-BBS studyElizabeth Forsythe, Usha G Mallya, Min Yang, et al.
Orphanet Journal of Rare Diseases|July 6, 2023
Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry surveyElizabeth Forsythe, Usha G Mallya, Min Yang, et al.
The Journal of Urology|April 18, 2007
Identification of a recurrent t(4;6) chromosomal translocation in prostate cancerTim M Lane, Jon C Strefford, Rafael J Yáñez-Muñoz, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2025
Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl SyndromeAndrea M Haqq, Christine Poitou, Wendy K Chung, et al.
EMBO Reports|January 11, 2021
Bardet-Biedl Syndrome ciliopathy is linked to altered hematopoiesis and dysregulated self-toleranceOksana Tsyklauri, Veronika Niederlova, Elizabeth Forsythe, et al.
Orphanet Journal of Rare Diseases|January 16, 2023
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial resultsElizabeth Forsythe, Robert M Haws, Jesús Argente, et al.
Journal of the American Society of Nephrology : JASN|September 24, 2016
Risk Factors for Severe Renal Disease in Bardet-Biedl SyndromeElizabeth Forsythe, Kathryn Sparks, Sunayna Best, et al.
The Lancet. Diabetes & Endocrinology|November 10, 2022
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label periodAndrea M Haqq, Wendy K Chung, Hélène Dollfus, et al.
The Journal of Clinical Endocrinology and Metabolism|April 27, 2026
Endocrine Characteristics in Bardet Biedl Syndrome from a Large Single-Centre Paediatric Multidisciplinary ClinicRachel S Varughese, Divya Pujari, Elizabeth Hatton, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2018
The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic PopulationSafa Mujahid, Katharine F Hunt, Yee S Cheah, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Orphanet Journal of Rare Diseases|July 6, 2023
Caregiver burden in Bardet-Biedl syndrome: findings from the CARE-BBS studyElizabeth Forsythe, Usha G Mallya, Min Yang, et al.
Orphanet Journal of Rare Diseases|July 6, 2023
Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry surveyElizabeth Forsythe, Usha G Mallya, Min Yang, et al.
The Journal of Urology|April 18, 2007
Identification of a recurrent t(4;6) chromosomal translocation in prostate cancerTim M Lane, Jon C Strefford, Rafael J Yáñez-Muñoz, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2025
Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl SyndromeAndrea M Haqq, Christine Poitou, Wendy K Chung, et al.
EMBO Reports|January 11, 2021
Bardet-Biedl Syndrome ciliopathy is linked to altered hematopoiesis and dysregulated self-toleranceOksana Tsyklauri, Veronika Niederlova, Elizabeth Forsythe, et al.
Orphanet Journal of Rare Diseases|January 16, 2023
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial resultsElizabeth Forsythe, Robert M Haws, Jesús Argente, et al.
Journal of the American Society of Nephrology : JASN|September 24, 2016
Risk Factors for Severe Renal Disease in Bardet-Biedl SyndromeElizabeth Forsythe, Kathryn Sparks, Sunayna Best, et al.
The Lancet. Diabetes & Endocrinology|November 10, 2022
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label periodAndrea M Haqq, Wendy K Chung, Hélène Dollfus, et al.
The Journal of Clinical Endocrinology and Metabolism|April 27, 2026
Endocrine Characteristics in Bardet Biedl Syndrome from a Large Single-Centre Paediatric Multidisciplinary ClinicRachel S Varughese, Divya Pujari, Elizabeth Hatton, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2018
The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic PopulationSafa Mujahid, Katharine F Hunt, Yee S Cheah, et al.
Pageof 3